Goldman Sachs Downgrades Novartis to Neutral, Raises Price Target to $121
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst James Quigley has downgraded Novartis from Buy to Neutral, while raising the price target from $119 to $121.
September 05, 2024 | 10:49 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has downgraded Novartis from Buy to Neutral, indicating a less bullish outlook, but raised the price target to $121, suggesting some positive expectations.
The downgrade from Buy to Neutral suggests a less optimistic view on Novartis' stock performance, which could lead to a neutral short-term impact on the stock price. However, the raised price target to $121 indicates some positive expectations, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100